News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
9,386 Results
Type
Article (80)
Company Profile (3)
Press Release (9303)
Section
Business (5398)
Career Advice (4)
Deals (632)
Drug Development (631)
FDA (176)
Job Trends (240)
News (6446)
Policy (196)
Tag
Academia (9)
Alliances (247)
Alzheimer's disease (11)
Antibody-drug conjugate (ADC) (6)
Approvals (182)
Artificial intelligence (2)
Autoimmune disease (1)
Automation (1)
Bankruptcy (1)
Best Places to Work (235)
Breast cancer (19)
Cancer (56)
Cardiovascular disease (10)
Career advice (3)
Career pathing (1)
CAR-T (1)
Cell therapy (4)
Clinical research (611)
Collaboration (7)
Compensation (8)
Complete response letters (1)
COVID-19 (6)
CRISPR (3)
C-suite (1)
Data (88)
Depression (2)
Diabetes (2)
Diagnostics (99)
Earnings (5579)
Events (680)
Executive appointments (2)
FDA (258)
Frontotemporal dementia (2)
Funding (12)
Gene editing (3)
Gene therapy (2)
GLP-1 (5)
Government (18)
Guidances (68)
Healthcare (290)
HIV (2)
Immunology and inflammation (1)
Infectious disease (6)
Inflammatory bowel disease (1)
Intellectual property (1)
IPO (511)
Job creations (19)
Job search strategy (2)
Layoffs (1)
Legal (21)
Liver cancer (1)
Longevity (1)
Lung cancer (4)
Lymphoma (10)
Manufacturing (5)
MASH (3)
Medical device (255)
Medtech (260)
Mergers & acquisitions (127)
Metabolic disorders (8)
Multiple sclerosis (1)
NASH (1)
Neurodegenerative disease (4)
Neuroscience (28)
NextGen: Class of 2026 (45)
Non-profit (21)
Obesity (3)
Ovarian cancer (2)
Pancreatic cancer (1)
Parkinson's disease (7)
Patents (1)
Patient recruitment (4)
People (263)
Pharmaceutical (1)
Pharmacy benefit managers (1)
Phase 1 (131)
Phase 2 (235)
Phase 3 (276)
Pipeline (300)
Postmarket research (22)
Preclinical (54)
Prostate cancer (6)
Radiopharmaceuticals (3)
Rare diseases (5)
Real estate (30)
Regulatory (179)
Reports (2)
Research institute (10)
Schizophrenia (3)
Service/supplier (1)
Sponsored (1)
Startups (10)
Stomach cancer (1)
Vaccines (1)
Weight loss (1)
Women's health (5)
Worklife (1)
Date
Last 7 days (12)
Last 30 days (55)
Last 365 days (587)
2026 (150)
2025 (583)
2024 (705)
2023 (807)
2022 (947)
2021 (958)
2020 (807)
2019 (556)
2018 (475)
2017 (344)
2016 (252)
2015 (335)
2014 (283)
2013 (180)
2012 (208)
2011 (286)
2010 (264)
Location
Africa (3)
Alabama (2)
Arizona (3)
Asia (419)
Australia (188)
California (250)
Canada (67)
China (10)
Colorado (16)
Connecticut (9)
Delaware (13)
Europe (795)
Florida (34)
Georgia (8)
Idaho (1)
Illinois (14)
India (1)
Indiana (15)
Japan (7)
Kentucky (3)
Louisiana (2)
Maine (4)
Maryland (30)
Massachusetts (222)
Michigan (4)
Minnesota (14)
Missouri (4)
New Hampshire (1)
New Jersey (64)
New York (66)
North Carolina (28)
Northern California (150)
Ohio (1)
Pennsylvania (60)
South America (8)
Southern California (88)
Tennessee (3)
Texas (24)
United States (917)
Utah (11)
Virginia (4)
Washington State (25)
9,386 Results for "434".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
March 30, 2026
·
4 min read
Press Releases
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
November 10, 2025
·
9 min read
Press Releases
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
September 15, 2025
·
8 min read
Press Releases
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
October 9, 2025
·
13 min read
Press Releases
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
November 5, 2025
·
18 min read
Press Releases
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
July 29, 2025
·
12 min read
Press Releases
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
April 29, 2025
·
8 min read
Press Releases
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
May 5, 2025
·
8 min read
Biotech Bay
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
Alterity Therapeutics today announced that new data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23-25, 2024 in Boston, MA.
April 10, 2024
·
8 min read
Biotech Bay
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
Alterity Therapeutics today announced that important new data on its lead drug candidate ATH434 was presented at the World Orphan Drug Congress USA 2024 in Boston.
April 29, 2024
·
6 min read
1 of 939
Next
